vs
Side-by-side financial comparison of Hologic (HOLX) and WATSCO INC (WSO). Click either name above to swap in a different company.
WATSCO INC is the larger business by last-quarter revenue ($1.6B vs $1.0B, roughly 1.5× Hologic). Hologic runs the higher net margin — 17.1% vs 4.5%, a 12.5% gap on every dollar of revenue. On growth, Hologic posted the faster year-over-year revenue change (2.5% vs -10.0%). WATSCO INC produced more free cash flow last quarter ($388.5M vs $215.2M). Over the past eight quarters, Hologic's revenue compounded faster (1.5% CAGR vs 0.4%).
Hologic, Inc. is an American medical technology company primarily focused on women's health; it sells medical devices for diagnostics, surgery, and medical imaging.
Watsco, Inc. is a distributor of air conditioning, heating and refrigeration equipment, and related parts and supplies (HVAC/R) in the United States. Watsco was founded more than 60 years ago as a manufacturer of parts, components, and tools used in the HVAC/R industry. In 1989, the company shifted from manufacturing to distribution, by acquiring Gemaire Distributors Inc., a South Florida-based Rheem distributor.
HOLX vs WSO — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.0B | $1.6B |
| Net Profit | $179.1M | $71.7M |
| Gross Margin | 56.0% | 27.1% |
| Operating Margin | 22.6% | 6.4% |
| Net Margin | 17.1% | 4.5% |
| Revenue YoY | 2.5% | -10.0% |
| Net Profit YoY | -10.9% | -25.9% |
| EPS (diluted) | $0.79 | $1.82 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.0B | $1.6B | ||
| Q3 25 | $1.0B | $2.1B | ||
| Q2 25 | $1.0B | $2.1B | ||
| Q1 25 | $1.0B | $1.5B | ||
| Q4 24 | $1.0B | $1.8B | ||
| Q3 24 | $988.0M | $2.2B | ||
| Q2 24 | $1.0B | $2.1B | ||
| Q1 24 | $1.0B | $1.6B |
| Q4 25 | $179.1M | $71.7M | ||
| Q3 25 | $187.2M | $161.6M | ||
| Q2 25 | $194.9M | $183.6M | ||
| Q1 25 | $-17.4M | $80.1M | ||
| Q4 24 | $201.0M | $96.8M | ||
| Q3 24 | $178.6M | $171.0M | ||
| Q2 24 | $194.5M | $181.4M | ||
| Q1 24 | $169.9M | $87.0M |
| Q4 25 | 56.0% | 27.1% | ||
| Q3 25 | 55.6% | 27.5% | ||
| Q2 25 | 56.3% | 29.3% | ||
| Q1 25 | 37.5% | 28.1% | ||
| Q4 24 | 56.8% | 26.7% | ||
| Q3 24 | 56.4% | 26.2% | ||
| Q2 24 | 55.4% | 27.1% | ||
| Q1 24 | 53.3% | 27.5% |
| Q4 25 | 22.6% | 6.4% | ||
| Q3 25 | 22.6% | 11.4% | ||
| Q2 25 | 24.9% | 13.2% | ||
| Q1 25 | -0.7% | 7.3% | ||
| Q4 24 | 22.5% | 7.8% | ||
| Q3 24 | 23.3% | 11.6% | ||
| Q2 24 | 24.1% | 12.6% | ||
| Q1 24 | 20.7% | 8.1% |
| Q4 25 | 17.1% | 4.5% | ||
| Q3 25 | 17.8% | 7.8% | ||
| Q2 25 | 19.0% | 8.9% | ||
| Q1 25 | -1.7% | 5.2% | ||
| Q4 24 | 19.7% | 5.5% | ||
| Q3 24 | 18.1% | 7.9% | ||
| Q2 24 | 19.2% | 8.5% | ||
| Q1 24 | 16.7% | 5.6% |
| Q4 25 | $0.79 | $1.82 | ||
| Q3 25 | $0.84 | $3.98 | ||
| Q2 25 | $0.86 | $4.52 | ||
| Q1 25 | $-0.08 | $1.93 | ||
| Q4 24 | $0.87 | $2.42 | ||
| Q3 24 | $0.75 | $4.22 | ||
| Q2 24 | $0.82 | $4.49 | ||
| Q1 24 | $0.72 | $2.17 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $2.4B | $733.3M |
| Total DebtLower is stronger | $2.5B | $361.6M |
| Stockholders' EquityBook value | $5.2B | $2.8B |
| Total Assets | $9.2B | $4.4B |
| Debt / EquityLower = less leverage | 0.48× | 0.13× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.4B | $733.3M | ||
| Q3 25 | $2.2B | $524.3M | ||
| Q2 25 | $1.9B | $293.0M | ||
| Q1 25 | $1.6B | $431.8M | ||
| Q4 24 | $2.0B | $781.9M | ||
| Q3 24 | $2.3B | $550.0M | ||
| Q2 24 | $2.4B | $424.9M | ||
| Q1 24 | $2.2B | $478.9M |
| Q4 25 | $2.5B | $361.6M | ||
| Q3 25 | $2.5B | $340.8M | ||
| Q2 25 | $2.5B | $338.7M | ||
| Q1 25 | $2.5B | $346.4M | ||
| Q4 24 | $2.5B | $337.2M | ||
| Q3 24 | $2.5B | $321.0M | ||
| Q2 24 | $2.5B | $307.1M | ||
| Q1 24 | $2.6B | $306.3M |
| Q4 25 | $5.2B | $2.8B | ||
| Q3 25 | $5.0B | $2.8B | ||
| Q2 25 | $4.8B | $2.8B | ||
| Q1 25 | $4.6B | $2.7B | ||
| Q4 24 | $4.8B | $2.7B | ||
| Q3 24 | $5.1B | $2.7B | ||
| Q2 24 | $5.0B | $2.6B | ||
| Q1 24 | $4.8B | $2.5B |
| Q4 25 | $9.2B | $4.4B | ||
| Q3 25 | $9.0B | $4.6B | ||
| Q2 25 | $8.8B | $4.7B | ||
| Q1 25 | $8.5B | $4.5B | ||
| Q4 24 | $8.7B | $4.5B | ||
| Q3 24 | $9.2B | $4.5B | ||
| Q2 24 | $8.9B | $4.4B | ||
| Q1 24 | $8.7B | $4.4B |
| Q4 25 | 0.48× | 0.13× | ||
| Q3 25 | 0.50× | 0.12× | ||
| Q2 25 | 0.52× | 0.12× | ||
| Q1 25 | 0.55× | 0.13× | ||
| Q4 24 | 0.53× | 0.13× | ||
| Q3 24 | 0.49× | 0.12× | ||
| Q2 24 | 0.51× | 0.12× | ||
| Q1 24 | 0.53× | 0.12× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $229.9M | $399.8M |
| Free Cash FlowOCF − Capex | $215.2M | $388.5M |
| FCF MarginFCF / Revenue | 20.5% | 24.6% |
| Capex IntensityCapex / Revenue | 1.4% | 0.7% |
| Cash ConversionOCF / Net Profit | 1.28× | 5.57× |
| TTM Free Cash FlowTrailing 4 quarters | $1.0B | $535.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $229.9M | $399.8M | ||
| Q3 25 | $355.1M | $354.9M | ||
| Q2 25 | $343.3M | $-7.4M | ||
| Q1 25 | $169.4M | $-177.6M | ||
| Q4 24 | $189.3M | $378.9M | ||
| Q3 24 | $367.0M | $232.8M | ||
| Q2 24 | $405.8M | $57.7M | ||
| Q1 24 | $292.4M | $103.7M |
| Q4 25 | $215.2M | $388.5M | ||
| Q3 25 | $341.4M | $346.1M | ||
| Q2 25 | $330.5M | $-14.3M | ||
| Q1 25 | $153.9M | $-185.2M | ||
| Q4 24 | $172.5M | $370.9M | ||
| Q3 24 | $350.6M | $223.0M | ||
| Q2 24 | $385.3M | $51.3M | ||
| Q1 24 | $279.6M | $97.9M |
| Q4 25 | 20.5% | 24.6% | ||
| Q3 25 | 32.5% | 16.7% | ||
| Q2 25 | 32.3% | -0.7% | ||
| Q1 25 | 15.3% | -12.1% | ||
| Q4 24 | 16.9% | 21.1% | ||
| Q3 24 | 35.5% | 10.3% | ||
| Q2 24 | 38.1% | 2.4% | ||
| Q1 24 | 27.5% | 6.3% |
| Q4 25 | 1.4% | 0.7% | ||
| Q3 25 | 1.3% | 0.4% | ||
| Q2 25 | 1.3% | 0.3% | ||
| Q1 25 | 1.5% | 0.5% | ||
| Q4 24 | 1.6% | 0.5% | ||
| Q3 24 | 1.7% | 0.5% | ||
| Q2 24 | 2.0% | 0.3% | ||
| Q1 24 | 1.3% | 0.4% |
| Q4 25 | 1.28× | 5.57× | ||
| Q3 25 | 1.90× | 2.20× | ||
| Q2 25 | 1.76× | -0.04× | ||
| Q1 25 | — | -2.22× | ||
| Q4 24 | 0.94× | 3.91× | ||
| Q3 24 | 2.05× | 1.36× | ||
| Q2 24 | 2.09× | 0.32× | ||
| Q1 24 | 1.72× | 1.19× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
HOLX
| Molecular Diagnostics | $255.3M | 24% |
| Breast Imaging | $219.9M | 21% |
| Services | $216.4M | 21% |
| Capital Equipment Componentsand Software | $187.2M | 18% |
| Cytology Perinatal | $76.0M | 7% |
| Interventional Breast Solutions | $71.2M | 7% |
| Blood Screening | $8.4M | 1% |
| Other Typeof Revenue | $5.4M | 1% |
WSO
Segment breakdown not available.
